Deutsche Bank Ag\ Prelude Therapeutics Inc Transaction History

Deutsche Bank Ag\

$245 Billion
Q1 2025

A detailed history of Deutsche Bank Ag\ transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Deutsche Bank Ag\ holds 80,723 shares of PRLD stock, worth $65,385. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,723

Previous 123,899 34.85%

Holding current value

$65,385

Previous $157,000 60.51%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$0.64 - $1.39 $27,632 - $60,014	-43,176 Reduced 34.85%	80,723 $62,000
Q4 2024 Feb 14, 2025	BUY	$0.8 - $2.04 $87,424 - $222,933	109,281 Added 747.58%	123,899 $157,000
Q3 2024 Jun 26, 2025	SELL	$2.07 - $6.37 $136,837 - $421,088	-66,105 Reduced 81.89%	14,618 $30,000
Q2 2024 Jun 12, 2025	SELL	$3.32 - $5.63 $219,468 - $372,171	-66,105 Reduced 81.89%	14,618 $55,000
Q2 2024 Aug 14, 2024	BUY	$3.32 - $5.63 $48,531 - $82,299	14,618 New	14,618 $55,000
Q3 2023 Nov 09, 2023	BUY	$2.74 - $4.79 $1,222 - $2,136	446 New	446 $1,000
Q2 2022 Aug 11, 2022	SELL	$4.0 - $7.55 $24,748 - $46,711	-6,187 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$6.9 - $13.22 $4,830 - $9,254	-700 Reduced 10.16%	6,187 $43,000
Q4 2021 Feb 11, 2022	BUY	$11.89 - $31.74 $4,161 - $11,109	350 Added 5.35%	6,887 $86,000
Q3 2021 Nov 04, 2021	SELL	$25.78 - $38.65 $788,764 - $1.18 Million	-30,596 Reduced 82.4%	6,537 $205,000
Q2 2021 Aug 11, 2021	BUY	$28.63 - $44.3 $15,660 - $24,232	547 Added 1.5%	37,133 $1.06 Million
Q1 2021 May 13, 2021	BUY	$39.27 - $91.68 $1.17 Million - $2.74 Million	29,836 Added 442.01%	36,586 $1.59 Million
Q4 2020 Feb 16, 2021	BUY	$28.81 - $88.94 $194,467 - $600,345	6,750 New	6,750 $483,000

Others Institutions Holding PRLD

# of Institutions

Shares Held

28.3M

Call Options Held

23.9K

Put Options Held

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $29.5M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account